Aktienanalyse zu Equillium Inc (EQ)EQEquillium Inc

Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its EQ302 is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. EQ101 is a clinical-stage, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which are key disease-driving, clinically validated cytokine targets to address unmet needs across a range of immuno-inflammatory indications. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the modulation of effector T cells. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Equillium Inc is a good buy right now due to its current price of $1.38, which is significantly below the analyst price targets of $20 and $6, indicating substantial upside potential. The RSI is at 53.339, suggesting a neutral momentum, while the stock has recently shown a 5-day change of +10.40%, indicating positive short-term performance. However, the main risk is the negative net income, with a loss of $5.3 million projected for Q1 2026, which investors should consider.

2 analysts cover EQ: 2 rate it Buy, 0 Hold and 0 Sell.